Table 3.
Inhibition values (IC50, lM) of several verticipyrone analogues determined by MTT assay using human and mouse cell linesa
| Compound | MCF-7 | MCF-10A | CRL-2365 | CRL-2366 | A549 | 3LL |
|---|---|---|---|---|---|---|
| 1 | 23.2 ± 0.6 | 9.9 ± 0.3 | 29.9 ± 0.6 | >31 | 20.7 ± 0.6 | 22.2 ± 5 |
| 12 | >31 | >31 | >31 | >31 | >31 | >31 |
| 13 | >31 | >31 | >31 | >31 | >31 | >31 |
| 14 | >31 | >31 | >31 | >31 | >31 | >31 |
| 16 | 3.3 ± 0.3 | 5.3 ± 0.3 | 3.3 ± 2.4 | 2.7 ± 0.3 | 5.3 ± 0.1 | 0.39 ± 0.07 |
| 17 | 3.3 ± 0.3 | 5.6 ± 0.3 | 2.4 ± 0.3 | 3.3 ± 1.5 | 4.1 ± 0.3 | 0.34 ± 0.05 |
| 18 | >31 | >31 | >31 | >31 | >31 | >31 |
| 28 | >27 | 15.1 ± 0.8 | >27 | >27 | >27 | 17.3 ± 1.7 |
| 30 | 17.4 ± 0.9 | 9.2 ± 0.2 | 12.4 ± 0.9 | 19.5 ± 0.7 | 17.0 ± 0.9 | 13.5 ± 0.2 |
a
Cell Type: MCF-7 (breast carcinoma); MCF-10A (‘normal’ human breast); CRL-2365 (brain glioblastoma); CRL-2366 (DNA repair deficient brain glioblastoma); A549 (lung carcinoma); 3LL (mouse Lewis lung carcinoma). DMSO was used as vehicle in the testing.